hepatitis-c

Documents about hepatitis-c

• Metformin Therapy in HCV Infection#633854ClinicalTrials.gov
• Expanding the Pool in Lung Transplantation#831424ClinicalTrials.gov
• Characterization of Clonal B Cell Populations in HCV Infection#855540ClinicalTrials.gov
• Drug-Drug Interaction Study in Healthy Subjects#877152ClinicalTrials.gov
• Novel targeted recruitment strategies to increase Hepatitis C screening for people with mental health illness who inject drugs in the Perth South Primary Health Network#298395Figshare
• Cross-Sectional Analysis Of The Hepatitis C Care Cascade Among People Who Use Drugs In New Haven, Ct#401531EliScholar
• Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis#813372ClinicalTrials.gov
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis#895876ClinicalTrials.gov
• Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease#900963ClinicalTrials.gov
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care#901015ClinicalTrials.gov
• A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials#981405ClinicalTrials.gov
• Development of a rubella- hepatitis C virus-like particle vaccine platform#1041722University of Nottingham Repository
• Facilitated Telemedicine for Underserved Populations: Management of Chronic Hepatitis C Virus Infection. The TEAM-C Study#468655NCBI Bookshelf
• Primary liver cancer at tertiary healthcare facility in Guinea: a cross-sectional study#284225HAL (France)
• Strengthening, Guidance, Health, Empowerment#844605ClinicalTrials.gov
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3#852567ClinicalTrials.gov
• Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis#853429ClinicalTrials.gov
• Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin#853772ClinicalTrials.gov
• Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection#860945ClinicalTrials.gov
• A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment#871300ClinicalTrials.gov
• An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens#879912ClinicalTrials.gov
• A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection#891331ClinicalTrials.gov
• Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)#917111ClinicalTrials.gov
• Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy#967336ClinicalTrials.gov
• Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania#982246ClinicalTrials.gov
• Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals#612227eScholarship
• Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain#860844ClinicalTrials.gov
• Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort#904989ClinicalTrials.gov
• Truenat™ HCV RNA Assay Evaluation#827723ClinicalTrials.gov
• Ribavirin, Its Dosing Regime#839557ClinicalTrials.gov
• Direct Acting Antiviral-Post Authorization Safety Study#865721ClinicalTrials.gov
• Intravenous Interferon During Liver Transplant#882903ClinicalTrials.gov
• The Ribavirin Pregnancy Registry#907545ClinicalTrials.gov
• Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation#838284ClinicalTrials.gov
• Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users#842081ClinicalTrials.gov
• Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2)#865965ClinicalTrials.gov
• TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir#893806ClinicalTrials.gov
• Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)#863929ClinicalTrials.gov
• Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection#906420ClinicalTrials.gov
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)#825350ClinicalTrials.gov
• Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access#848280ClinicalTrials.gov
• Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy#869117ClinicalTrials.gov
• A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis#881375ClinicalTrials.gov
• TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin#884125ClinicalTrials.gov
• Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection#887224ClinicalTrials.gov
• Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study#684030eScholarship
• Assessing the Safety of Direct-Acting Antivirals for Hepatitis C—A PCORnet Study#2387NCBI Bookshelf
• Utility of MicroRNAs for Diagnosing Hepatocellular Carcinoma in Hepatitis C Patients#803481ClinicalTrials.gov
• Virological Response Study of the HCV Vaccine IC41#863748ClinicalTrials.gov
• Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial#885998ClinicalTrials.gov